Karyn O'Neil, PhD

Chief Scientific Officer at Ar­o Biotherapeutics

Speaker

Karyn O’Neil is the CSO, Aro Biotherapeutics. She is a co-inventor on the Centyrin patents and has led the team focused on advancing the Centyrin targeting platform since its inception. At Aro, Karyn’s team is applying protein engineering, nucleic acid chemistry and chemical conjugation technologies to enable Centyrin – mediated intracellular delivery of nucleic acid cargos in a cell specific manner. Most recently, the Aro team has completed a Phase 1a trial in NHVs demonstrating the utility of the Centyrin-siRNA platform for tissue targeted siRNA delivery and initiated a Phase 1b trial in patients with Pompe Disease. Karyn received her PhD from the University of Pennsylvania where she focused on protein engineering and protein biophysics.